2月26日，君实生物-U盘中上涨7.41%，截至13:20，报30.74元/股，成交2.72亿元，换手率1.2%，总市值303.0亿元。
资料显示，上海君实生物医药科技股份有限公司位于中国(上海)自由贸易试验区海趣路36、58号2号楼10层1003室，公司是一家专注于创新疗法的发现、开发和商业化的生物制药公司，主要业务涵盖肿瘤免疫疗法、自身免疫系统疾病、慢性代谢类疾病、神经系统疾病、感染类疾病等治疗领域。公司凭借卓越的创新药物发现能力、先进的生物技术研发、全产业链大规模生产技术和极具市场潜力的在研药品组合，具有极高的市场潜力。
截至9月30日，君实生物-U股东户数2.95万，人均流通股3.34万股。
2024年1月-9月，君实生物-U实现营业收入12.71亿元，同比增长28.87%；归属净利润-9.27亿元，同比增长34.12%。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.